Literature DB >> 31835147

Oral flavonoid fisetin treatment protects against prolonged high-fat-diet-induced cardiac dysfunction by regulation of multicombined signaling.

Lin-Feng Hu1, Jing Feng1, Xianling Dai1, Yan Sun1, Mingxin Xiong1, Lili Lai1, Shaoyu Zhong1, Chao Yi1, Geng Chen1, Huanhuan Li1, Qiufeng Yang1, Qin Kuang1, Tingting Long1, Jianxia Zhan1, Tingting Tang1, Chenxu Ge2, Jun Tan3, Minxuan Xu4.   

Abstract

Excess high-fat diet (HFD) intake predisposes the occurrence of obesity-associated heart injury, but the mechanism is elusive. Fisetin (FIS), as a natural flavonoid, has potential activities to alleviate obesity-induced metabolic syndrome. However, the underlying molecular mechanisms of FIS against HFD-induced cardiac injury remain unclear. The present study was to explore the protective effects of FIS on cardiac dysfunction in HFD-fed mice. We found that FIS alleviated HFD-triggered metabolic disorder by reducing body weight, fasting blood glucose and insulin levels, and insulin resistance. Moreover, FIS supplements significantly alleviated dyslipidemia in both mouse hearts and cardiomyocytes stimulated by metabolic stress. FIS treatment abolished HFD-induced inflammatory response in heart tissues through suppressing TNF receptor-1/TNF receptor-associated factor-2 (Tnfr-1/Traf-2) signaling. Furthermore, FIS induced a strong reduction in the expression of fibrosis-related genes, contributing to the inhibition of fibrosis by inactivating transforming growth factor (Tgf)-β1/Smads/Erk1/2 signaling. Collectively, these results demonstrated that FIS could be a promising therapeutic strategy for the treatment of obesity-associated cardiac injury.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fisetin; Insulin resistance and dyslipidemia; Metabolic syndrome; Tgf-β1/Smads/Erk1/2; Tnfr-1/Traf-2

Mesh:

Substances:

Year:  2019        PMID: 31835147     DOI: 10.1016/j.jnutbio.2019.108253

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  1 in total

1.  Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy.

Authors:  Giuseppe Di Lorenzo; Luca Scafuri; Ferdinando Costabile; Liuba Pepe; Anna Scognamiglio; Felice Crocetto; Germano Guerra; Carlo Buonerba
Journal:  Future Sci OA       Date:  2022-02-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.